NasdaqGM - Nasdaq Real Time Price USD

Intellia Therapeutics, Inc. (NTLA)

8.32
-0.23
(-2.69%)
At close: May 13 at 4:00:01 PM EDT
8.39
+0.07
+(0.84%)
After hours: May 13 at 7:58:18 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
45,569
57,877
36,275
52,121
33,053
Operating Expense
586,636
592,140
551,566
510,285
300,903
Operating Income
-541,067
-534,263
-515,291
-458,164
-267,850
Net Non Operating Interest Income Expense
43,778
47,807
49,832
8,542
1,283
Other Income Expense
-28,625
-32,565
-15,733
-24,564
-1,325
Pretax Income
-525,914
-519,021
-481,192
-474,186
-267,892
Net Income Common Stockholders
-525,914
-519,021
-481,192
-474,186
-267,892
Diluted NI Available to Com Stockholders
-525,914
-519,021
-481,192
-474,186
-267,892
Basic EPS
-5.23
-5.25
-5.42
-6.16
-3.78
Diluted EPS
-5.23
-5.25
-5.42
-6.16
-3.78
Basic Average Shares
100,848.50
98,849
88,770
76,972
70,894
Diluted Average Shares
100,848.50
98,849
88,770
76,972
70,894
Total Operating Income as Reported
-541,067
-534,263
-515,291
-458,164
-267,850
Total Expenses
586,636
592,140
551,566
510,285
300,903
Net Income from Continuing & Discontinued Operation
-525,914
-519,021
-481,192
-474,186
-267,892
Normalized Income
-497,289
-486,456
-481,092
-460,701
-267,892
Interest Income
43,778
47,807
49,832
8,542
1,283
Net Interest Income
43,778
47,807
49,832
8,542
1,283
EBIT
-541,067
-534,263
-515,291
-458,164
-267,850
EBITDA
-530,796
-523,978
-506,315
-450,592
-260,959
Reconciled Depreciation
10,271
10,285
8,976
7,572
6,891
Net Income from Continuing Operation Net Minority Interest
-525,914
-519,021
-481,192
-474,186
-267,892
Total Unusual Items Excluding Goodwill
-28,625
-32,565
-100
-13,485
0
Total Unusual Items
-28,625
-32,565
-100
-13,485
0
Normalized EBITDA
-502,171
-491,413
-506,215
-437,107
-260,959
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 5/6/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BEAM Beam Therapeutics Inc.
18.05
-1.04%
 
EDIT Editas Medicine, Inc.
1.5000
-2.60%
 
CRSP CRISPR Therapeutics AG
37.22
-0.98%
 
VERV Verve Therapeutics, Inc.
4.1600
-4.37%
 
IOVA Iovance Biotherapeutics, Inc.
1.7900
-7.25%
 
PRME Prime Medicine, Inc.
1.2700
-5.22%
 
SRPT Sarepta Therapeutics, Inc.
36.20
-0.47%
 
CRBU Caribou Biosciences, Inc.
0.7828
-4.31%
 
DNA Ginkgo Bioworks Holdings, Inc.
8.12
-2.29%
 
RXRX Recursion Pharmaceuticals, Inc.
4.5100
-2.80%